Publications in collaboration with researchers from Eli Lilly and Company (2)

2021

  1. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

    Journal of Clinical Oncology, Vol. 39, Núm. 10, pp. 1108-1118

2020

  1. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

    BMC Cancer, Vol. 20, Núm. 1